Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape

Drawing on new discussions from ARDD2025 in Copenhagen, the focus turns to how GLP-1s, IPF, and the gut microbiome are steering aging drug development

Over the past decade, aging research has transitioned from a mostly fundamental science practice, including a landmark introduction of 9 hallmarks of aging back in 2013 and its expanded version of 12 hallmarks in 2023, to a highly technical, multidisciplinary field with increasingly tangible practical potential.

This transformation is happening thanks to numerous advances in the biology of aging, including the emergence of age-specific biomarkers or “aging clocks,” senolytics, cell reprogramming, and many other promising directions.

But it is also enabled by the rapid advent of foundational technologies, such as artificial intelligence (AI), which has opened doors for more sophisticated biology modeling, better understanding of aging processes, and potentially new creative ideas for addressing humanity’s biggest current limitation: the inevitable decline and end of life.

In this issue: Is the first anti-aging drug class on the horizon? — Finding the missing link between aging research and clinical development — Do bacteria in our gut hold the key to healthspan and longevity?